The Foundation is pleased to announce that the following six new research projects will be funded for 2014-2015: "The use of KO and KI mice, a human fibroblast model and Sacs mini-gene in the search of a treatment for ARSACS" - Bernard Brais. "Role of neurofilaments...
Preliminary work with Olivier Lambercy from Zurich paid off
October 17,2014. Following a visit by Olivier Lambercy, a Swiss researcher to Saguenay back in September 2012 to present research from his laboratory, we are pleased that the preliminary work has paid off. We are beginning the process of analyzing the results of its...
ARSACS research team article published in the Oxford Journals
October 06,2014-The ARSACS research team article, under the direction of Dr. Bernard Brais, has been published in the Oxford Journals of the prestigious Oxford University. The abstract of the article"Sacs knockout mice present pathophysiological defects underlying...
Outcome of the Board meeting
June 24, 2014. At the meeting of the Board held on 9 June in Montreal, there was discussion on the new cell model being developped and its potential use for screening large banks of therapeutic molecules. The new strategy being pursued and its first results were also...
Dr. Paola Giunti receives research funding
The Foundation is pleased to announce that it will fund the research of Dr. Paola Giunti (ULC Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, UK) under its current research funding program. Her work entitled "Design and Validation...
Meeting concerning the development of a possible drug
As previously mentioned, a meeting for drug discovery work related to the sacsin will be held in Montreal. The meeting has been scheduled for July 14, 2014. The sacsin is the protein involved in ARSACS.
Millipore signs a commercialization agreement
A commercialization agreement of the sacsin antibody was signed between Millipore and one of the ARSACS research team members. Millipore is a large US-based company and a major distibutor of commercial antibodies. With this agreement, the Foundation expects that other...
BBRC in the UK funding ARSACS related research
Dr Paul Chapple, a member of the Foundation research team located in London, has received funding from the Biotechnology and Bioscience Research Council in the UK to better understand the sacsin's role in mitochondrial dynamics, which is an important element in ARSACS...
Research results analysis
Members of the ARSACS research team, Dre Roxanne Larivière, Rébecca Gaudet and Dr Bernard Brais,analyze the latest results of the research.
E-Rare 2 competition
The ARSACS research team of canadians and europeans has filed on January 30,2014 a pre-application to obtain financing as part of the E-Rare 2 competition on rare diseases. The final decision will be made on October 31, 2014.
The Foundation finances Olivier Audet’s project
The Foundation will provide a $5000 research grant to Olivier Audet to pursue his study with ARSACS patients. In March 2013, we informed you that Olivier, a student in the Masters Program in experimental medicine at the University of Québec à Chicoutimi(UQAC), had...
Meeting of ARSACS research team
The ARSACS research team met on January 14, 2014 in Montreal. Attached is a summary of the meeting.
Second phase of a trial project
A short trial conducted in 2013 and consisting of administering a drug to the ARSACS transgenic mice had some encouraging results. The mice improved their physical performance. The second phase of this project will start in February 2014. This time, the drug will be...
Short Video on ARSACS
January,2014- In a short video, Dr Brais is describing the ARSACS and the major research milestones achieved in the last five years. Please note that the audio is in French only. See it Here